Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer

NCT01104259 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT01104259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01104259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer
Lead sponsor
University of Washington
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2010
Completion date
April 30, 2017
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor-negative breast cancer, her2-negative breast cancer, hereditary breast/ovarian cancer - brca1, hereditary breast/ovarian cancer - brca2, male breast cancer, progesterone receptor-negative breast cancer, recurrent breast cancer, stage iv breast cancer, triple-negative breast cancer